Arana begins Phase II
Thursday, 11 December, 2008
Arana Therapeutics has begun its Phase II trial of its domain antibody ART621 for rheumatoid arthritis.
The trial, which will recruit 200 patients, will held in eight countries, including Australia, the US and India.
It will test the efficacy of ART621 in rheumatoid arthritis and will compare three doses of ART621 with a placebo in patients also taking methotrexate, a common anti-metabolite that inhibits the metabolism of folic acid.
Results are due in mid-2010.
Common arthritis drug also lowers blood pressure
Scientists have known for a while that methotrexate helps with inflammation, but it may also help...
AI enables precise gene editing
A newly developed tool utilises AI to predict how cells repair their DNA after it is cut by gene...
Shingles vaccine may reduce risk of heart attack and stroke
Vaccination with either the recombinant herpes zoster vaccine or the live-attenuated zoster...
